OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management’s participation in the following...
Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement...
Raises Full Year 2026 Revenue and Cash Outlook Driven by Continued Business Momentum Conference Call to Begin Today at 4:30 p.m. ET
VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (“bsADC”) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ:...
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report...
OmniAb, Inc. (NASDAQ:OABI) , a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku...
OmniAb (NASDAQ:OABI) reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and associated...
Conference Call Begins at 4:30 p.m. Eastern Time Today
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences over the coming weeks. ...